Atyr Pharma, Stock Performance
| ATYR Stock | 3.44 0.15 4.56% |
ATyr Pharma, holds a performance score of 17 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.75, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ATyr Pharma,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding ATyr Pharma, is expected to be smaller as well. Use ATyr Pharma, sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to analyze future returns on ATyr Pharma,.
Risk-Adjusted Performance
17 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in aTyr Pharma, are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, ATyr Pharma, reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 4.56 | Five Day Return 14.67 | Year To Date Return 98.84 | Ten Year Return 98.84 | All Time Return 98.84 |
Last Split Factor 1:14 | Last Split Date 2019-07-01 |
1 | aTyr started at buy by Jefferies, citing efzofitimod potential | 09/05/2024 |
2 | aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal | 10/02/2024 |
3 | aTyr Pharma Inc Reports Q3 Revenue of 0.353 Million, GAAP EPS Loss of 0. ... | 11/07/2024 |
4 | Why Are Short Sellers Focusing More on Atyr Pharma | 11/14/2024 |
5 | aTyr Pharma stock rated Buy Lucid notes Efzofitimods potential in lung diseases - Investing.com | 11/19/2024 |
| Begin Period Cash Flow | 13.1 M | |
| Free Cash Flow | -37.4 M |
ATyr |
ATyr Pharma, Relative Risk vs. Return Landscape
If you would invest 187.00 in aTyr Pharma, on August 30, 2024 and sell it today you would earn a total of 157.00 from holding aTyr Pharma, or generate 83.96% return on investment over 90 days. aTyr Pharma, is currently generating 1.0634% in daily expected returns and assumes 4.7722% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than ATyr, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ATyr Pharma, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ATyr Pharma,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as aTyr Pharma,, and traders can use it to determine the average amount a ATyr Pharma,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2228
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ATYR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.77 actual daily | 42 58% of assets are more volatile |
Expected Return
| 1.06 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average ATyr Pharma, is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ATyr Pharma, by adding it to a well-diversified portfolio.
ATyr Pharma, Fundamentals Growth
ATyr Stock prices reflect investors' perceptions of the future prospects and financial health of ATyr Pharma,, and ATyr Pharma, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ATyr Stock performance.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (106.33) % | ||||
| Current Valuation | 79.38 M | ||||
| Shares Outstanding | 75.8 M | ||||
| Price To Book | 1.76 X | ||||
| Price To Sales | 244.92 X | ||||
| Revenue | 353 K | ||||
| EBITDA | (52.18 M) | ||||
| Net Income | (50.39 M) | ||||
| Total Debt | 15.1 M | ||||
| Book Value Per Share | 1.08 X | ||||
| Cash Flow From Operations | (33.22 M) | ||||
| Earnings Per Share | (0.90) X | ||||
| Market Capitalization | 144.01 M | ||||
| Total Asset | 120.65 M | ||||
| Retained Earnings | (468.02 M) | ||||
| Working Capital | 86.58 M | ||||
About ATyr Pharma, Performance
Assessing ATyr Pharma,'s fundamental ratios provides investors with valuable insights into ATyr Pharma,'s financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ATyr Pharma, is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.53) | (0.55) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.56) | (0.58) |
Things to note about aTyr Pharma, performance evaluation
Checking the ongoing alerts about ATyr Pharma, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for aTyr Pharma, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| aTyr Pharma, appears to be risky and price may revert if volatility continues | |
| aTyr Pharma, was previously known as ATyr Pharma and was traded on NASDAQ Exchange under the symbol LIFE. | |
| The company reported the previous year's revenue of 353 K. Net Loss for the year was (50.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ATyr Pharma, generates negative cash flow from operations | |
| aTyr Pharma, has a frail financial position based on the latest SEC disclosures | |
| About 64.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: aTyr Pharma stock rated Buy Lucid notes Efzofitimods potential in lung diseases - Investing.com |
- Analyzing ATyr Pharma,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ATyr Pharma,'s stock is overvalued or undervalued compared to its peers.
- Examining ATyr Pharma,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ATyr Pharma,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of ATyr Pharma,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ATyr Pharma,'s stock. These opinions can provide insight into ATyr Pharma,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ATyr Stock Analysis
When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.